, Volume 7, Issue 2, pp 97-98
Date: 23 Mar 2011

Medical treatment of colonic diverticular disease: are we sure the aim is right?

This is an excerpt from the content

Colonic diverticular disease (DD) is one of the most common gastrointestinal conditions afflicting Western populations, with an estimated mortality in Europe of more than 20,000 per year [1]. Although most patients with DD remain asymptomatic, about one-third will develop symptoms at some point in their lives, symptoms that range from chronic mild abdominal pain to acute episodes of diverticulitis complicated by abscess or frank colonic perforation [2].

Thus, it is not surprising that, given the frequency of the condition, the therapeutic aspects are mainly devoted to try to prevent the occurrence of complications occurring in these patients, mainly the onset of diverticulitis. Among the several new therapeutic options, paralleling more traditional therapeutic approaches (dietary fibers, antibiotics, etc.) [3], the use of mesalazine has been recently proposed [4].

Why use mesalazine to treat DD? The main working hypothesis is that the chronic mucosal inflammation seen in this condition i ...